Modulating mitophagy in mitochondrial disease by Dombi, E. et al.
This is a repository copy of Modulating mitophagy in mitochondrial disease.




Dombi, E., Mortiboys, H. and Poulton, J. (2017) Modulating mitophagy in mitochondrial 





Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless 
indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by 
national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of 
the full text version. This is indicated by the licence information on the White Rose Research Online record 
for the item. 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
  1 
 XXX -XXX/14 $58.00+.00 © 2014 Bentham Science Publishers 
 
Modulating mitophagy in mitochondrial disease   
Eszter Dombia, Heather Mortiboysb, and Joanna Poulton*a 
 
aNuffield Department of Obstetrics and Gynaecology, University of Oxford, Oxford, United Kingdom 
bSheffield Institute for Translational Neuroscience, Neuroscience Department, University of Sheffield, United 
Kingdom 
Abstract: Mitochondrial diseases may result from mutations in the maternally-inherited m ochondrial DNA 
(mtDNA) or from mutations in nuclear genes encoding mitochondrial proteins. Their bi-genomic nature makes 
mitochondrial diseases a very heterogeneous group of disorders that can prese t at any age and can affect any 
type of tissue. 
The autophagic-lysosomal degradation pathway plays an important role in clearing dysfunctional and redundant 
mitochondria through a specific quality control mechanism termed mitophagy.  Mitochondria could be targeted for 
autophagic degradation for a variety of reasons including basal turnover for recycling, starvation induced degradation, and 
degradation due to damage. While the core autophagic machinery is highly conserved and common to most pathways, the 
signaling pathways leading to the selective degradation of damaged mitochondria are still not completely understood.  
Type 1 mitophagy due to nutrient starvation is dependent on PI3K (phosphoinositide 3-kinase) for autophagosome 
formation but independent of mitophagy proteins, PINK1 (PTEN-induce  putative kinase 1) and Parkin. Whereas type 2 
mitophagy that occurs due to damage is dependent on PINK1 and Parkin but does not require PI3K.   
Autophagy and mitophagy play an important role in human disease and hence could serve as therapeutic targets for the 
treatment of mitochondrial as well as neurodegenerative disorders. Therefore, we reviewed drugs that are known 
modulators of autophagy (AICAR and metformin) and may effect this by activating the AMP-activated protein kinase 
signaling pathways. Furthermore, we reviewed data available on supplements, such as Coenzyme Q and the quinone 
idebenone, that we assert rescue increased mitophagy in mitochondrial disease by benefiting mitochondrial function. 
Keywords: Mitophagy, AICAR, metformin, Coenzyme Q10, idebenone, phenanthroline 
1. INTRODUCTION 
 Mitochondrial disease comprises a group of disorders 
ultimately caused by dysfunctional mitochondria. 
Mitochondria are cellular organelles of bacterial origin [1] 
that are often referred to as the ‘power house’ of the cell. 
However, in addition to generating energy mitochondria 
fulfil a number of roles in order to maintain cellular 
homeostasis, such as participating in calcium storage [2], 
iron metabolism and haem synthesis [3, 4], apoptosis [5, 6] 
and thermogenesis [7].  
Mitochondria have their own genome, transmitted 
maternally, comprising 37 genes in total, all essential for its 
function. Human mitochondrial DNA (mtDNA) encodes 13 
proteins (7 subunits of Complex I, 1 subunit of Complex III, 
3 subunits of Complex IV, and 2 subunits of the F1F0-
ATPase) along with the 22tRNAs and 2 rRNAs necessary 
for their translation [1]. Mitochondrial disease may  
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result from mutations in the mitochondrial genome as well as 
from mutations in nuclear genes encoding proteins required 
for mitochondrial function. As a result of this bi-genomic 
nature mitochondrial disease can have recessive, dominant, 
X-linked or maternal inheritance.  
 Disorders of mitochondrial oxidative phosphorylation 
(OXPHOS) are common inborn errors of metabolism.  While 
1 individual in 400 carries a common mtDNA mutation that 
causes presbycusis [8], the incidence of clinically diagnosed 
mitochondrial disease is nearer 1 in 4300 in adults, making it 
one of the commonest  adult forms of inherited neurological 
disorders [9].  
 Mutations in mtDNA cause a number of diseases, which 
primarily affect tissues with high energy demand such as 
muscle and neural tissue. In many of these, mutant and 
normal mtDNA co-exist in the same individual 
(heteroplasmy).  Clinical severity is often influenced by the 
proportion of mutant mtDNA present within cells.  Many of 
these diseases are progressive, presumably because the 
mutant load increases with time.  However, homoplasmic 
mtDNA mutations also exist when the entire mitochondrial 
pool harbours mutant mtDNA.  Symptoms tend to present as 
a single acute episode rather than as progressive disease.  
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clinically heterogeneous group of disorders that can present 
at any age and can affect any type of tissue.  
 Dysfunctional or redundant mitochondria are selectively 
degraded by a specialized form of macro-autophagy, termed 
mitophagy [10-12]. Mitochondrial quality control is an 
important aspect of cellular homeostasis, especially in post-
mitotic tissues as mitophagy protects against the release of 
pro-apoptotic proteins, production of reactive oxygen species 
and ineffective generation of ATP by damaged or aged 
mitochondria. Regulation of the mitochondrial life cycle and 
the maintenance of a robust functional population within 
cells are achieved by a fine balance between mitochondrial 
turnover and biogenesis [13, 14]. 
2. MITOPHAGY 
2.1. Mitophagy in outline 
Mitophagy is one of the major mechanisms of 
mitochondrial quality control and the only known pathway to 
turn over whole mitochondrial genomes. Mitochondria could 
be targeted for autophagic degradation for a variety of 
reasons including basal turnover for recycling, starvation 
induced degradation, and degradation due to damage. The 
core autophagic machinery is evolutionaril y highly 
conserved and the signaling cascades mediate both bulk and 
selective autophagic processes [12, 15]. Damaged or 
depolarized mitochondrial fragments are engulfed by the 
autophagosome, an organelle that is central to macro-
autophagy.  Key features of this stage are recruitment and 
lipidation of LC3 (microtubule-associated protein-1 light 
chain-3) to the autophagosome, and recognition of cargo by 
adapter molecules then interaction with LC3-ll (the lipidated 
form of LC3).  Acidification and degradation of the cargo 
follow formation of an autolysosome by fusion with a 
lysosome. 
2.2. The mammalian target of rapamycin 
 The mammalian target of rapamycin (mTOR) is a key 
regulator of autophagy dependent of the cell’s metabolic 
status (Fig. 1). Under nutrient rich conditions mTOR inhibits 
autophagy. Association of mTOR with Raptor forms the 
mTORC1 complex [16]. Phosphorylation of Atg13 by 
mTOR prevents the assembly of the ULK1 (uncoordinated 
51-like kinase 1)- Atg13-FIP200 complex [17, 18] that 
would activate autophagic signaling downstream of 
mTORC1[18, 19]. AMP-activated protein kinase (AMPK) is 
a component of an evolutionary conserved kinase cascade. 
AMPK is a sensor of cellular energy regulated by upstream 
kinases such as the tumor suppressor, LKB1[20]. An 
increase in AMP: ATP ratio triggers the AMPK signaling 
cascade which results in the downregulation of anabolic 
pathways and any non-essential ATP consuming operations 
while activating catabolic processes that generate ATP [21, 
22]. Activation of AMPK also results in the downregulation 
of mTOR activity and therefore induction of autophagy [23] 
through the phosphorylation of ULK1 at Ser 317 and Ser 777 
[11]. Egan et al. showed that the loss of AMPK or ULK1 in 
mammals leads to defective mitophagy and that 
phosphorylation of ULK1 by AMPK is an essential step 
[24]. 
2.3. Elongation of the isolation membrane and closure of 
the autophagosome 
 The class III phosphoinositide 3-kinase (PI3K) complex 
composed of Atg14, the class III PI3K Vps (vacuolar protein 
sorting) 34 and Beclin-1, is required for early steps of 
autophagosome nucleation and expansion of autophagosome 
formation [25, 26] (Fig. 2). However, it was shown that 
Beclin-1 independent pathways exist. Chu et al., 
demonstrated that 3-methyladenine (3MA) and wortmannin 
(PI3K inhibitors), as well as the knock-down of Beclin-1 in 
SH-SY5Y neuroblastoma cells, failed to decrease MPP+ (1-
methyl-4-phenylpyridinium, the active metabolite of 
parkinsonian neurotoxin MPTP and Complex I inhibitor) 
induced mitophagy [27]. Two ubiquitin-like modifications, 
the Atg (autophagy-associated protein) 12 and LC3 
(microtubule-associated protein-1 light chain-3) 
conjugations, are essential for membrane elongation and 
autophagosome formation respectively [17, 25] (Fig. 2). The 
C-terminal glycine of Atg12 is conjugated to an Atg5 lysine 
residue mediated by Atg7, an ubiquitin-activating enzyme 
(E1)-like enzyme [17].  LC3 is the mammalian orthologue 
of the yeast Atg8 protein. Upon activation of autophagy 
cytosolic LC3 (LC3-I) becomes conjugated to 
phosphatidylethanolamine via Atg7 (E1-like enzyme) and 
Atg3 (E2-like enzyme) [28] generating LC3-II . LC3-II can 
then be recruited to autophagosomes forming punctate 
structures.  LC3-II positive autophagosomes are often used 
as markers to characterize autophagy [29].   
2.4 Selective degradation of damaged mitochondria 
 The signaling pathways leading to the selective 
degradation of damaged mitochondria are still not 
completely understood. The nature of the specific molecules 
involved seems to be dependent on the trigger and therefore 
there are multiple mechanisms by which mitochondria can 
be targeted for degradation.   
 Parkin, an E3 ubiquitin ligase [30], is recruited to 
depolarized mitochondria by PINK1 (PTEN-induced 
putative kinase 1) [31]. Parkin promotes mitophagy by the 
ubiquitination of mitochondrial outer membrane proteins and 
the recruitment of ubiquitin binding autophagic components 
like HDAC6 and p62 [32]. Lazarou et al. investigated the 
involvement of autophagy receptors in mitophagy and found 
that NDP52 (nuclear dot protein 52 kDa) and OPTN 
(optineurin) are recruited to mitochondria by PINK1 where 
they redundantly mediate mitophagy.  They are also 
involved in the recruitment of the upstream autophagic 
machinery [33].The authors also confirm previous findings 
that p62 is essential for the formation of perinuclear clusters 
of damaged mitochondria, however, dispensable for 
mitophagy [34, 35]. In mammals the mitophagy pathway that 
is essential for programmed clearance of mitochondria 
during erythrocyte maturation is mediated by ???? [36, 37]. 
Nix acts as an adaptor protein by directly binding to LC3 
through its amino-terminal LC3-interacting region (LIR) 
[38]. Nix was also shown to contribute to mitochondrial 
Modulating mitophagy in mitochondrial disease 3 
priming, following CCCP-induced depolarization, by 
controlling the mitochondrial translocation of Parkin. It is 
also involved in the recruitment of the autophagic 
machinery. Ding et al. reported that under conditions of 
CCCP-induced stress GFP-LC3 punctae formation required 
Nix and the presence of ROS in HeLa cells [39]. 
 Mitochondrial morphology also plays an important role 
in the clearance of unwanted mitochondria as fragmentation 
is believed to be a pre-requisite for mitophagy to occur [40]. 
On the other hand, stress-induced mitochondrial hyperfusion, 
a response to selective stresses such as starvation, spares 
mitochondria from autophagic degradation, increases 
mitochondrial ATP production and promotes cell survival 
[41, 42]. Human sirtuins (SIRTs) target a variety of 
molecules in order to coordinate certain aspects of cellular 
metabolism [43, 44]. SIRT3 localizes to mitochondria and in 
addition to stimulating the transcription factor FOXO3 
(forkhead box O3) [45] it also regulates mitochondrial 
dynamics by targeting the outer membrane fusion protein 
OPA1 (optic atrophy 1) [46], this provides an additional 
“druggable“ target for modulating mitophagy.  
2.5. Type 1 and type 2 mitophagy 
 Recently, mitophagy was classified into different 
categories by Lemasters based on the involvement of the 
PI3K complex in the formation of autophagosomes and of 
Pink1 and Parkin.  This contrasts with the myriad of reports 
claiming that each of these is indispensable for 
autophagosome formation. Mitophagy induced by nutrient 
deprivation was designated as type 1 mitophagy and this is 
independent of PINK1 and Parkin. Autophagosome 
formation during type 1 mitophagy is inhibited by 3-MA and 
wortmannin, inhibitors of PI3K.  Mitophagy induced by 
photodamage was referred to as type 2 mitophagy and 
involves PINK1 and Parkin. This was not inhibited by the 
above mentioned PI3K inhibitors [47]. 
3. AUTOPHAGY AND HUMAN DISEASE 
 Autophagy is essential for normal development both in 
humans [48] and other species [49] defects resulting in 
severe malformation syndromes.  Further, autophagic 
dysfunction is associated with a number of conditions such 
as neurodegeneration, cancer and ageing. Monoallelic 
deletion of Beclin1 is a common feature of human breast, 
ovarian and prostate cancer  [50].  
 Impaired mitochondrial quality control via autophagy 
appears to play a key role in many types of Parkinson’s 
disease [32, 51], suggesting that mitophagy is particularly 
important for the affected tissue, substantia nigra.  Hence 
mtDNA mutations accumulate in substantia nigra in many 
different types of Parkinson’s disease [add reference Bender 
et al 2006 and 2008].  However, in vivo experiments have 
not greatly supported its importance, largely because of 
technical difficulties. Mitophagy is increased in cell cultures 
from various mitochondrial disorders such as mitochondrial 
encephalomyopathy, lactic acidosis, and stroke-like episodes 
(MELAS) [52-54], complex I deficiency [55], and even in 
Alzheimer’s.  It appears to be protective in heteroplasmic 
disease [52] but is potentially harmful in disorders that cause 
excessive mitochondrial fragmentation [56]. Hence, drugs 
that modulate mitophagy hold promise as therapies for these 
diseases. Indeed, heteroplasmic cybrid cells harbouring 
deleterious COXI mutations underwent a shift towards wild-
type mtDNA when exposed to long-term overexpression of 
Parkin. In parallel cytochrome c oxidase activity was also 
restored [57]. Indeed overexpression of Parkin is protective 
in many forms of Parkinson’s, which could be due to its 
mitophagy effects [58]. It is reasonable to assume that 
autophagy and mitophagy could be a therapeutic target for 
the treatment of not just mitochondrial disease but 
neurodegenerative disorders and cancer as well. 
4. DRUG MODULATORS OF MITOPHAGY 
 While there have been several scholarly reviews of drug 
modulators of autophagy [59], much less comparable 
information is available specifically targeting mitophagy.  
Park et al. developed a cell line in which LC3 was tagged 
with GFP and mitochondria with YFP and screened the 
LOPAC1250TM Chemical Library of 1200 
pharmacologically active compounds and the Prestwick 
Chemical library (1200 FDA approved medicines) for drugs 
that fragmented mitochondria and increased the number of 
autophagosomes [60]. These investigators identified 
phenanthroline, an extremely useful laboratory tool, as a 
candidate activator of mitophagy.  However there is a large 
area of uncertainty regarding the use of drugs for modulating 
mitophagy in patients.   
As mitophagy is a specific subtype of macro-autophagy that 
depends on the availability of autophagosomes and most of 
the proteins in that pathway, the autophagy findings are 
largely applicable.  Several stages of the autophagy process 
are “druggable”.  Activation of AMPK and/or inhibition of 
mTORC1 by various stress signals induces activation of the 
ATG1–ULK1 complex and this increases autophagy.  The 
best known such agent is probably rapamycin which 
stabilizes the raptor-mTOR association by forming a 
complex with the immunophilin FK506–binding protein of 
12 kDa (FKBP12) and thereby inhibits the kinase activity of 
mTOR [61]. Amiodarone is another mTORC1 inhibitor that 
also affects calcium channels [62]. An important signaling 
ascade that controls mTORC1 is the PI3 kinase pathway. 
Class I and III PI3 kinases have opposite effects on 
autophagy; their activity either inhibiting (class I) or 
accelerating (class III) the process [59]. Autophagy can be 
attenuated by inhibiting class III PI3K activity with 3-
methyladenine (3-MA), wortmannin and 2-(4-morpholinyl)-
8-phenylchromone (LY294002). Upstream of these, AMPK 
activation downregulates mTOR and hence activates 
autophagy [23]. For example, the sugar trehalose, whose 
mechanism is usually held to be rescue of protein 
misfolding, is now known to inhibit glucose transporters in 
the GLUT class [63] and hence activate AMPK.  
 A significant group of drugs modulate mitophagy via the 
phosphoinositol signaling pathway, a pathway that is 
independent of mTORC1.  For example, lithium, 
carbamazepine and valproic acid reduce the intracellular 
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inositol level and hence activate autophagy [59].  Of these 
lithium is known to be an inhibitor of mitophagy [64]. 
Lysosomal inhibitors also slow autophagy and mitophagy, 
the antimalarial drug, chloroquine, being a well-known 
example that prevents lysosomal acidification and 
proteolysis  [65]. 
 The specific triggers for mitophagy include impaired 
mitochondrial function and/or mitochondrial depolariztion 
and mitochondrial fragmentation.  These processes are 
closely interlinked and all are partially rescued by 
mitochondrial stress responses associated with mitochondrial 
elongation [41, 42]. For instance, impaired mitochondrial 
function inhibits mitochondrial fusion, and hence is 
frequently associated with mitochondrial fragmentation [66]. 
The drug, mitochondrial division inhibitor 1 (Mdivi-1) 
specifically inhibits the pro-fission mitochondrial protein, 
dynamin related protein-1 (Drp-1) [67] and this lengthens 
mitochondria.  This drug is being investigated as a possible 
therapy in heart failure from multiple causes [68] its mode of 
action potentially involving inhibition of mitophagy.   
 We [56] and others [69] showed that excessive 
mitochondrial fragmentation associated with profound 
knockdown of the pro-fusion protein, OPA1, is associated 
with loss of mtDNA and loss of mitochondrial membrane 
potential.  Phenanthroline activates mitophagy by impairing 
OPA1 processing and hence function [60]. It results in 
excessive fragmentation that drives mitophagy, but this is 
non-selective [53]. Furthermore, reduced OPA1 activity is 
associated with impaired activation of its GTPase domain, 
modulated by acetylation and rescued by the mitochondrial 
deacetylase SIRT3 [46]. In addition, respiratory chain 
inhibitors are likely to increase mitophagy by inhibiting 
mitochondrial fusion [66], including those that do not 
depolarize mitochondria, such as oligomycin. We have 
previously identified drugs which increase mitochondrial 
function in Parkin mutant cells; it will be interesting to 
assess the effects of these compounds on mitophagy rates in 
these cells [70]. In particular ursodeoxycholic acid (UDCA) 
which was identified in this screen and is used in the 
treatment of biliary cirrhosis has been shown to stop 
increases in LC3-II formation in the rat intestine [71]. 
 A recent study investigates Urolithin A [72] a component 
of pomegranate juice, that is able to increase mitophagy in c. 
elegans, mice and rats.  As little as 6 weeks treatment is able 
to improve motor performance in elderly rodents.  While this 
is extremely promising, the increase in mitophagy is 
accompanied by decreased complex 1 activity and 
presumably compensatory increase in complex ll.  The 
increase in mitophagy might thus be an appropriate response 
driven by impaired mitochondrial function, a characteristic 
that is likely to limit its clinical usefulness.       
  Given that there are no established treatments for 
mitochondrial disease involving drug modulators of 
mitophagy, despite their likely usefulness in heteroplasmic 
mtDNA disease, we will focus the remainder of this review 
on specific drugs for which clinical data are available. 
 
5. INCREASED MITOPHAGY IN MITOCHONDRIAL 
DISEASE CAN BE RESCUED BY SPECIFIC 
THERAPIES 
5.1. Coenzyme Q10 
 Coenzyme Q10 (CoQ10) is an essential electron and 
proton carrier in the mitochondrial respiratory chain (MRC), 
transferring electrons from complexes I and II to complex III 
[73]. Primary deficiencies of CoQ are rare. However, many 
patients undergo a therapeutic trial and anecdotally report 
benefit.  Furthermore, an increasing number of disorders 
involving the mitochondrial electron transport chain (ETC) 
are associated with secondary CoQ10 deficiency [52, 74]. 
Investigation of MELAS fibroblasts from two patients 
harboring the m.3243G>A mtDNA mutation revealed a 
significant reduction in the activity of all of the 
mitochondrial respiratory chain complexes and additionally 
an over 40% reduction in CoQ10 levels when compared to 
controls. This secondary CoQ10 deficiency was associated 
with an increased degradation of mitochondria via 
mitophagy [52].  
 In a screen for effective pharmacological treatments for 
MELAS syndrome CoQ10 was identified as one of top 
candidates [75]. Furthermore, CoQ10 was able to rescue 
respiratory defects in yeast A14G, harbouring a mutation 
equivalent to the homoplasmic human m.3243A > G 
mutation. The effect of CoQ10 was further investigated in 
fibroblasts derived from a MELAS patient. CoQ10 
supplementation significantly increased the proliferation rate 
of MELAS fibroblasts along with cellular ATP levels 
without any effect on control cells. Additionally, CoQ10 
treatment rescued the decreased MRC activity of patient 
cells. Increased autophagic activity was shown in MELAS 
fibroblasts (using lysotracker and LC3-II western). CoQ10 
treatment attenuated this increase [75].   
 The etiology of numerous other neurodegenerative 
disorders is believed to involve dysfunctional mitochondria 
potentially because of oxidative stress. CoQ10 has shown 
beneficial effects in several animal models of 
neurodegenerative diseases including amyotrophic lateral 
sclerosis, Huntington’s disease, and Parkinson’s disease 
[76].  While data from clinical trials has failed to show any 
effect of the oxidised form of CoQ10 [77], the reduced form 
has shown some benefit in a small clinical trial [78]. 
Exogenous administration of CoQ10 was shown to be 
neuroprotective during iron induced mitochondrial damage 
and apoptosis in human dopaminergic neurons (SK-N-SH) 
[79]. 
5.2. Idebenone 
 Idebenone [2,3-dimethoxy- 5-methyl-6-(10-
hydroxydecyl)-1,4-benzoquinone] is a synthetic analogue of 
coenzyme Q [80] able to scavenge a variety of free radical 
species as well as prevent lipid peroxidation [81]. Idebenone, 
along with other short-chain quinones, has a certain energy 
rescue capacity in case of complex I dysfunction. These 
compounds are able bypass complex I and by shuttling 
electrons directly from the cytoplasm to complex III of the 
mitochondrial respiratory chain to produce ATP [82].  
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 Idebenone was reported to benefit patients with Leber’s 
hereditary optic neuropathy (or LHON, a nonsyndromic 
mitochondrial optic neuropathy) [83]. In a small study it also 
improved respiratory function in patients with Leigh 
syndrome [84]. We showed that mitophagy is increased in 
fibroblasts from two independent families who were 
homoplasmic for the m.13051G>A pathogenic mtDNA 
mutation, in association with a Leigh –LHON phenotype 
with increased ROS production [55]. This missense mutation 
causes a Ser for Gly substitution in ND5, but without 
measurable complex l deficiency. When one patient 
harboring the m.13051G>A mtDNA mutation was given 
idebenone her vision improved.  Treatment of patient 
derived fibroblasts harboring this mutation with idebenone 
increased cell viability and attenuated the previously 
observed increased mitophagy [55]. This reduced mitophagy 
suggests that the idebenone directly benefited mitochondrial 
function, potentially by rescuing the increased ROS 
production.     
 
6. MODULATORS OF AMPK AND MITOPHAGY 
6.1. Metformin 
 One of the most widely used orally administered 
treatment for type 2 diabetes is metformin. Metformin 
decreases hyperglycemia and has beneficial effects on 
circulating lipids, without affecting insulin secretion [68, 
69].  It also has neuro-protective [70], cardio protective [71] 
and tumour-suppressive potential [85]. Metformin is a 
known activator of AMPK [72, 73], an effect that is required 
for metformin’s inhibitory effect on glucose production by 
hepatocytes [74]. It activates autophagy by both AMPK-
dependent [75] and –independent pathways [76]. As 
discussed above, AMPK phosphorylates ULK1 [11] thus 
inducing autophagy by downregulating mTOR activity [20]. 
This contrasts with metformin’s AMPK-independent 
pathway for increasing autophagy by activating the sirtuin 
class of histone/protein deacetylases (SIRT1)- FOXO 
pathway, activated by increased NAD+ [76]. The same 
group also showed that metformin treatment facilitates 
Parkin-mediated type 2 mitophagy by decreasing the 
expression of cytosolic p53 and increasing degradation of 
mitofusins [77]. However, in our quantitative assay of 
mitophagy, combining high content fluorescence microscopy 
and mitochondrial DNA load, we showed that metformin 
strongly inhibits mitophagy under energetic stress [53].  
When patient derived fibroblasts harboring the common 
m.3243G>A mtDNA mutation are forced to use their 
mitochondria by growing on glucose-free galactose-based 
media, the mutant mtDNA is progressively cleared by type 1 
mitophagy.  Treatment of these cells with metformin for 7 
days decreased the clearance of mutant mtDNA compared to 
untreated cells [53]. This suggests that while metformin 
activates type 2 mitophagy and macro-autophagy, it inhibits 
type 1 mitophagy.  It is unlikely that this inhibition of type 1 
mitophagy reflects an unexpected beneficial effect of 
metformin on mitochondrial function that enables the cells to 
tolerate a higher mutant load than untreated cells, which 
would parallel that of idebenone (above).  This is because the 
m.13051G>A mutant cells grew better in idebenone and we 
did not see a robust growth advantage to m.3243G>A in 
metformin under energetic stress up to 72 hours. On the 
other hand, metformin treatment of cells over expressing 
alpha synuclein (a major component in many forms of 
Parkinson’s) has proved effective in increasing cell viability 
and abolished the toxic effects of alpha synucelin [86]. In 
addition metformin has shown to be protective in other 
models of Parkinson’s [87, 88] and Alzheimer’s [89]. 
6.2. AICAR 
 5-aminoimidazole-4-carboxamide riboside (AICAR) is 
transported into cells by adenosine transporters and 
converted by adenosine kinase into monophosphorylated 
nucleotide 5-aminoimidazole-4-carboxamide-1-
dribofuranosyl-5-monophosphate (ZMP), an intermediate 
product that mimics the activating effect of AMP on the 
AMPK system [90]. Golubitzky et al. investigated the effect 
of active small molecules in patient derived fibroblasts with 
Complex I deficiency. Three parameters; growth, ROS 
production and ATP production; were measured after 72 
hours treatment. The effect of small molecules was assessed 
in galactose media as it is void of substrates for glycolysis 
and cell growth is dependent on OXPHOS. The screen 
identified AICAR as the most favorable compound with 
positive effects on multiple parameters in five out of six 
patient derived fibroblasts. Further investigation of AICAR 
in a representative cell line (NDUFS2) revealed increased 
cell growth and mitochondrial content upon treatment [91]. 
While these investigators did not investigate mitochondrial 
morphology, mitophagy or direct phosphorylation of PGC-
1g (proliferator-activated receptor gamma coactivator 
1alpha) [92], any of these could contribute to the changes 
seen. 
 Indeed, increased mitochondrial content could be the 
result of AMPK acting via the direct phosphorylation of 
PGC-1g [92], a well-established regulator of mitochondrial 
biogenesis [93, 94]. Activation of the AMPK signalling 
cascade by AICAR treatment induces PGC-1g expression 
demonstrated by increased mRNA levels [58, 92]. 
AICAR treatment was also deemed beneficial to 
ibroblasts derived from MELAS patients with increased 
autophagosome accumulation. Treatment with this AMPK-
activator increased cell proliferation rates, decreased ROS 
levels and alleviated the accumulation of autophagosomes, 
and the authors attributed this to increasing autophagosome 
turnover [95]. In neither of these studies was the effect of 
AICAR on mitochondrial morphology considered.  Other 
authors showed that AICAR fragments mitochondria in 
glucose media [96]. We confirmed this and found that it 
increases the lengthening of mitochondria under energetic 
stress (unpublished data). As elongated mitochondria 
generally have increased mass and cellular ATP content with 
reduced mitophagy, this could be the mechanism underlying 
Golubitzky’s findings.  Neither does it directly conflict with 
the findings of Garrido-Maraver, who cultured their cells in 
much higher glucose concentrations 
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 Duchenne muscular dystrophy (DMD) is characterized 
by myofiber death from apoptosis or necrosis and DMD 
muscles often harbor dysfunctional mitochondria [97]. 
Activation of the autophagy-mitophagy cascade via AICAR 
treatment was shown to alleviate the phenotype of the mdx 
mice [98] the current animal model for Duchenne muscular 
dystrophy (DMD) [99]. AICAR was also shown to have a 
strong and cancer-specific anti-growth effect which could be 
attributed to its affects in mitochondrial apoptotic signaling 
[100]. 
 AICAR treatment of alpha synuclein over-expressing 
cells reduced the increase in LC3 II conversion caused by 
alpha synuclein toxicity and increased cell viability, having a 
similar effect to metformin (discussed above, [86]). 
 
7. USING MEASUREMENTS OF MITOPHAGY AS 
OBJECTIVE SUPPORT FOR CLINICAL BENEFIT 
 Because there are no treatments for the vast majority of 
patients with mitochondrial disease, clinicians are frequently 
asked to prescribe co-factors and supplements that are 
unlikely to significantly benefit their patients.  It is difficult 
to confirm improvement objectively as there are no good 
biomarkers and clinical scales can only confirm substantial 
changes. Measuring changes in physical activity requires a 
high level of patient compliance that may be too great for 
these often severely disabled patients.  Hence a means of 
demonstrating pharmacological benefit to individual patients 
at the cellular level would be clinically useful.  Having 
developed high throughput methods for measuring 
mitophagy in fibroblast cultures  [53], our clinical 
experience provisionally suggests that we can use a 
combination of improved cell growth and reduction in 
mitophagy in tissue culture to support our clinical findings. 
 
CONCLUSIONS 
 Even though mitophagy studies have not yet identified 
drugs that can be used to treat mitochondrial specific by 
targeting mitophagy specifically, we anticipate they will do 
so in the medium term.  Such processes are likely to be 
important in drugs commonly used to treat mitochondrial 
patients and may well underlie the unexplained effects of 
small molecules such as AICAR.  In the interim, mitophagy 
assays can be used as functional studies of cell cultures from 
individual patients who feel their disease is helped by 
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